Global Allergy Immunotherapy Market is valued at approximately USD 2.07 billion in 2022 and is anticipated to grow with a growth rate of more than 9.0% over the forecast period 2023-2030. Allergy immunotherapy is a medical treatment for allergies. It is a long-term therapy that aims to desensitize a person’s immune system to specific allergens, such as pollen, dust mites, pet dander, or certain insect venoms. The goal of allergy immunotherapy is to modify the immune response to allergens, leading to a reduction in allergy symptoms. It can be effective in treating allergic rhinitis (hay fever), allergic asthma, and insect venom allergies. Allergy shots can provide long-term relief, even after the treatment is completed. The Allergy Immunotherapy market is expanding because of factors such as the increasing burden of various types of allergies and rising demand for personalized medicine.
According to Information form the American College of Allergy, Asthma & Immunology, more than 50 million Americans suffer from allergies each year. In addition, for instance, a journal paper published by SingleCare in January 2022 estimates that more than 50.0 million Americans experience an allergy of some form each year. Similarly, The number of cases of asthma in Indian senior citizens across the India in 2050 was anticipated to be about 25.4 million cases. Furthermore, it noted that allergies rank as the sixth-most prevalent chronic illness in the US. In addition, a survey conducted by SingleCare in 2021 found that 82.0% of respondents who had allergies felt their allergies had an impact on their quality of life in the US. Thus, rising incidence of allergies across the regions is driving the market growth. In addition, technological advancements in sublingual dosage formulations and presence of strong product pipeline are creating a lucrative opportunity to the market growth. However, the high cost of allergy immunotherapy research and drawbacks associated with the use of allergy immunotherapy and availability of alternative treatments stifles market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Allergy Immunotherapy Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 with largest market share owing to the dominance of key market players, rising prevelance of allergy disorders, rising number of product launch activities in the region. Whereas, Asia Pacific region is projected to have fastest growth owing to factors such as rising disease prevelance, rising expansion by key market players in the region as well as rising number of awareness programs in the region.
Major market player included in this report are:
Torii Pharmaceutical Co., Ltd.
HAL Allergy Group
Jubliant Pharma (Hollister Allergy)
Merck KGaA (Allergopharma)
Recent Developments in the Market:
Ø In January 2023, HollisterStier Allergy unveiled Ultrafiltered Dog, its most recent product innovation. Patients who are sensitive to dogs can be diagnosed and treated successfully with the product.
Ø In June 2022, ALK began a phase I clinical research in North America for their brand-new sublingual tablet intended to treat peanut allergy.
Global Allergy Immunotherapy Market Report Scope:
ü Historical Data – 2020 – 2021
ü Base Year for Estimation – 2022
ü Forecast period – 2023-2030
ü Report Coverage – Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
ü Segments Covered – Treatment Type, Allery Type, Distribution Channel, Region
ü Regional Scope – North America; Europe; Asia Pacific; Latin America; Middle East & Africa
ü Customization Scope – Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Treatment Type:
Subcutaneous Immunotherapy (SCIT)
Sublingual Immunotherapy (SLIT)
By Allergy Type:
By Distribution Channel:
Middle East & Africa
Rest of Middle East & Africa